Last $153.84 USD
Change Today -1.15 / -0.74%
Volume 683.5K
PRGO On Other Exchanges
New York
Tel Aviv
As of 6:40 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

perrigo co plc (PRGO) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/28/14 - $168.39
52 Week Low
08/28/13 - $115.94
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PERRIGO CO PLC (PRGO)

perrigo co plc (PRGO) Details

Perrigo Company Public Limited Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API) primarily in the United States, Israel, the United Kingdom, Mexico, and Australia. Its Consumer Healthcare business offers various OTC and nutrition products, including analgesics, cough and cold remedies, and gastrointestinal and feminine hygiene products, as well as vitamins, dietary supplements, and nutritional drinks. The company’s Nutritionals business develops, manufactures, markets, and distributes infant formula, pediatric nutritionals and vitamins, minerals, and supplements primarily under the Centrum, One-A-Day, Flintstones, and Osteo-Bi-Flex brands. Its Rx Pharmaceuticals business develops, manufactures, and markets a portfolio of generic prescription drugs in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, and oral liquids and oral solid dosage forms. The company’s Active Pharmaceutical Ingredients (API) business develops, manufactures, and markets differentiated APIs and finished dosage forms for the branded and generic pharmaceutical industries. In addition, Perrigo Company Public Limited Company is developing TYSABRI for the treatment of multiple sclerosis and crohn’s disease; and ELND005 for the treatment of Alzheimer’s disease and bipolar disorder. Its Pharmaceutical and Medical Diagnostic Products business markets and manufactures branded prescription drugs under licenses; and imports other pharmaceutical and medical diagnostic products. The company sells its products to drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations. Perrigo Company Public Limited Company was founded in 1887 and is headquartered in Dublin, Ireland.

9,900 Employees
Last Reported Date: 08/15/13
Founded in 1887

perrigo co plc (PRGO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $526.3K
Executive Vice President of Global Operations...
Total Annual Compensation: $452.5K
Executive Vice President, General Counsel and...
Total Annual Compensation: $452.5K
Executive Vice President and General Manager ...
Total Annual Compensation: $441.0K
Compensation as of Fiscal Year 2013.

perrigo co plc (PRGO) Key Developments

Perrigo Receives AB Therapeutic Equivalent Rating from the FDA for Testosterone Gel 1.0%

Perrigo Company announced that it has received an AB therapeutic equivalent rating from the U.S. Food and Drug Administration (FDA) for its previously approved New Drug Application (NDA) for testosterone gel 1.0%. FDA concluded that Perrigo's testosterone product is therapeutically equivalent to [AbbVie's] AndroGel 1% and can be substituted with the full expectation that it will produce the same clinical effect and safety profile as AndroGel 1% when used under the conditions specified in the labeling. Other companies that have submitted NDAs referencing AndroGel(R) 1.0% have failed to achieve the AB rating. Androgel(R) 1.0% (testosterone gel 1.0%) is indicated to treat adult males who have low or no testosterone.

Perrigo Reportedly Up For Sale

Perrigo Company Public Limited Company (NYSE:PRGO) has reportedly hired an investment bank to consider its sale through a merger with a major pharmaceutical firm, sourced informed. In response to the report, Perrigo said, "The company does not respond to rumors."

Perrigo Company Announces FDA Final Approval for the Store Brand Equivalent to Advil(R) Congestion Relief Tablets, 200 Mg/10 Mg

Perrigo Company announced that it was the first to receive final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for ibuprofen and phenylephrine hydrochloride tablets, 200 mg/10 mg (over-the-counter), the store brand equivalent to Advil(R) Congestion Relief Tablets, 200 mg/10 mg. Perrigo expects to begin shipments of the product prior to the upcoming cough/cold/flu season. Advil(R) Congestion Relief Tablets, 200 mg/10 mg, (ibuprofen & phenylephrine hydrochloride tablets, 200 mg/10 mg) is indicated for the relief of sinus pressure, nasal swelling and congestion, and headache. Estimated annual sales of the product are approximately $18 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $153.84 USD -1.15

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 2,770 INR +25.70
Endo International PLC $66.97 USD -1.56
Hospira Inc $51.84 USD +0.12
Mead Johnson Nutrition Co $96.05 USD +1.41
Mylan Inc/PA $50.53 USD -1.21
View Industry Companies

Industry Analysis


Industry Average

Valuation PRGO Industry Range
Price/Earnings 85.5x
Price/Sales 5.3x
Price/Book 2.4x
Price/Cash Flow 108.1x
TEV/Sales 4.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at